SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.
SynZeal will update these details as per new development or finding in product specification without further noticed.
化学名称: 4-Chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-(methoxy-d3)-2-methylpyrimidin-5-amine
Shipping Temperature: Ambient
HSN Code: 38229010
Country of Origin: India
微笑: CC1=NC(OC([2H])([2H])[2H])=C(NC2=NCCN2)C(Cl)=N1
Moxonidine-d3 is chemically 4-Chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-(methoxy-d3)-2-methylpyrimidin-5-amine. Moxonidine-d3 is supplied with detailed characterization data compliant with regulatory guideline. Moxonidine-d3 can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Moxonidine.
The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.
Determination of moxonidine and its impurities by thinlayer chromatography
Slavica Filipic1 , Musbah Salem Mohamed Shenger1 , Katarina Nikolic1 , Danica Agbaba
Journal of Liquid Chromatography & Related Technologies Volume 38, 2015 - Issue 11
Development and validation of reversed phase high performance liquid chromatographic method for determination of moxonidine in the presence of its impurities
Svetlana Milovanovic´ a, Biljana Otasevi ˇ c´ b, Mira Zecevi ˇ c´ b,∗, Ljiljana Zivanovi ˇ c´ b, Ana Protic
Journal of Pharmaceutical and Biomedical Analysis 59 (2012) 151–156
UPLC Method for Determination of Moxonidine and Its Degradation Products in Active Pharmaceutical Ingredient and Pharmaceutical Dosage Form
Biljana Otasˇevic´, Svetlana Milovanovic´, Mira Zecˇevic´, Jelena Golubovic´, Ana Protic
Chromatographia (2014) 77:109–118